| Revenue growth | 6% YoY |
|---|---|
| Margins | EBITDA margin 12.5%; 15.4% excluding one-time API impact. |
| Demand visibility | Strong base business growth across all geographies. |
Growth
Revenue grew 6% YoY but fell 7% QoQ. PAT declined 69% YoY to ₹443 Cr.
Outlook
Focus on peptide/biosimilar growth, resuming semaglutide supplies, and M&A. Net cash surplus remains healthy at ₹3,058 Cr.
Risks
Semaglutide API specification issues, Middle East conflict increasing freight/solvent costs, and US price erosion.
Investor Presentation filed with BSE, NSE: DRREDDY. Summary written with AI assistance from the document.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,203.80
- Market cap
- ₹1,00,478 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 31.2×Sector 47.3×
- Promoter holding
- 26.64%+0.01% QoQ
- FII holding
- 20.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Board Meeting Date
Dr. Reddy’s Laboratories will hold a board meeting on October 23, 2026, to approve the standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Reddy's Laboratories Partnership
Dr. Reddy's signed an exclusive distribution agreement with Takeda for Qdenga dengue vaccine in India's private market. No upfront consideration stated; availability expected H1 2027.
Dr. Reddy's Laboratories Price Movement Clarification
Dr. Reddy's confirmed a news report regarding a voluntary licensing agreement with Gilead Sciences for an HIV prevention drug, noting it is not material.
Dr. Reddy's Laboratories Business Update
Dr. Reddy's Laboratories received two observations from the USFDA following a records assessment of its API manufacturing facility in Jiutepec, Mexico.
Dr. Reddy's Laboratories Employee Stock Options
Dr. Reddy's Laboratories allotted 375 equity shares to employees upon the exercise of stock options under its ESOP scheme.
Dr. Reddy's Laboratories Employee Stock Options
Dr. Reddy's Laboratories allotted 4,110 equity shares to employees under its 2002 Employee Stock Option Scheme. The shares rank pari passu with existing equity.